Migdal Insurance & Financial Holdings Ltd. Beam Therapeutics Inc. Transaction History

Migdal Insurance & Financial Holdings Ltd.

$6.18 Billion
Q3 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 04, 2021	SELL	$64.12 - $128.71 $743,535 - $1.49 Million	-11,596 Closed	0 $0
Q1 2021 May 04, 2021	BUY	$71.28 - $120.75 $512,930 - $868,917	7,196 Added 163.55%	11,596 $928,000
Q4 2020 Feb 08, 2021	BUY	$22.24 - $95.63 $97,856 - $420,772	4,400 New	4,400 $359,000

Others Institutions Holding BEAM

# of Institutions

236

Shares Held

75.2M

Call Options Held

438K

Put Options Held

232K

Farallon Capital Management LLC San Francisco, CA

8.21M
Shares

$208 Million
1.01% of portfolio
Vanguard Group Inc Valley Forge, PA

7.84M
Shares

$198 Million
0.0% of portfolio
Black Rock Inc. New York, NY

7.63M
Shares

$193 Million
0.0% of portfolio
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl

6.53M
Shares

$165 Million
1.52% of portfolio
Arch Venture Management, LLC Chicago, IL

4.83M
Shares

$122 Million
71.21% of portfolio

View Full List

About Beam Therapeutics Inc.

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.78B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

More about BEAM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Migdal Insurance & Financial Holdings Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Migdal Insurance & Financial Holdings Ltd. with notifications on news.

Account